KD Pharma acquires Switzerland-based cannabinoid manufacturer PhytoXtract
The global CMO plans to have a complete, licensed cGMP manufacturing facility online by the end of 2021
KD Pharma has acquired the manufacturing assets of Switzerland-based cannabinoid manufacturer, PhytoXtract, giving the contract manufacturing organisation access to technology for producing active pharmaceutical ingredients (APIs) based on phytocannabinoids and other plant extracts.
The technology further expands KD Pharma’s lipid technology portfolio and can be used in combination with KD’s other fractionation and separation technologies.
Although the company specialises in lipid technology focused primarily on omega-3s, its technology suites can be applied to other lipid sources such as cannabinoids.
The assets from Phytoextract will provide KD Pharma with additional routes to develop new products for this emerging market.
Last June, KD Pharma signed a licensing agreement with Italy-based Herbolea Biotech for Bio-Herbolysis, a novel extraction method, that can process 300 kg/hour, in one process step, without the need for solvent.
KD Pharma expects to have a complete, licensed cGMP manufacturing facility online by the end of the year.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.